Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
NCT02916745 · View on ClinicalTrials.gov ↗
Study Summary
This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Canada. Participation will last 6 months.
Conditions Studied
Interventions
- DRUG Porfimer sodium
- DEVICE Fiber optic
Study Locations (7)
Florida
- University of Florida — Gainesville
Georgia
- Southeastern Regional Medical Center — Atlanta
Illinois
- Alexian Brothers Hospital Network — Elk Grove Village
Oklahoma
- Southwestern Regional Medical Center — Tulsa
Washington
- Providence Medical Research Center — Spokane
Wisconsin
- University of Wisconsin-Madison — Madison
Ontario
- Toronto General Hospital — Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916745
The ClinicalTrials.gov registry entry for NCT02916745 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concordia Laboratories, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions — of which Porfimer sodium is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02916745 reports 7 study locations spanning 7 distinct geographic areas — top geographies include Florida, Georgia, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02916745 about?
NCT02916745 is a clinical study titled "Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer". This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Cana...
What is the current status of trial NCT02916745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-01-26. Estimated completion is 2019-04-12.
What conditions does trial NCT02916745 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Lung Metastasis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02916745?
The interventions under investigation include: Porfimer sodium (DRUG), Fiber optic (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02916745?
This trial is sponsored by Concordia Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02916745 being conducted?
This trial has 7 study locations across Florida, Georgia, Illinois, Oklahoma, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.